Speaker
Description
Background:
Individuals with serious mental illness (SMI) face a disproportionate burden of metabolic syndrome, largely driven by second-generation antipsychotics, leading to reduced life expectancy. Concurrently, emerging neuroscience highlights the profound role of glucagon-like peptide-1 (GLP-1) receptors within the central nervous system (CNS) in modulating mood, reward pathways, and neuroinflammation.
Objective:
To review the clinical utility, central mechanisms, and therapeutic potential of GLP-1 receptor agonists in psychiatric practice, extending beyond weight management to cognitive enhancement and neuroprotection.
Method:
A synthesis of recent translational and clinical evidence—highlighted at the 2026 RCPsych International Congress—examining the CNS actions of GLP-1 agonists, their role in mitigating antipsychotic-induced obesity, and their emerging impact on mood disorders and neurodegenerative processes.
Results:
Mechanistic data confirms that GLP-1 receptors in the CNS influence synaptic plasticity and offer robust neuroprotective properties. Clinical updates demonstrate that GLP-1 therapy not only significantly reverses metabolic side effects in patients with SMI but also correlates with improvements in cognitive processing speed, executive function, and potential deceleration of cognitive decline in early-stage dementia.
Patient-reported outcomes underscore a dual benefit: profound improvements in physical vitality and an enhanced quality of life.
Conclusion:
GLP-1 receptor agonists represent a paradigm shift from reactive psychiatric care to a holistic, preventive wellness model.
Integrating these agents into Kenyan mental health treatment guidelines protocols offers a dual-action pathway to bridge the mortality gap in SMI and address cognitive deficits, aligning directly with proactive public health strategies